Analysts See $0.56 EPS for Pfizer Inc. (PFE)

January 21, 2018 - By Henry Gaston

 Analysts See $0.56 EPS for Pfizer Inc. (PFE)
Investors sentiment increased to 0.96 in Q3 2017. Its up 0.02, from 0.94 in 2017Q2. It is positive, as 53 investors sold Pfizer Inc. shares while 700 reduced holdings. 106 funds opened positions while 620 raised stakes. 4.06 billion shares or 0.86% more from 4.02 billion shares in 2017Q2 were reported.
Clarivest Asset Limited Liability Company holds 0% in Pfizer Inc. (NYSE:PFE) or 194 shares. Huber Mgmt Llc invested in 1.02 million shares or 1.99% of the stock. Hexavest holds 6.80M shares. 13,322 are held by Bender Robert &. Fulton Breakefield Broenniman Limited Liability Corp, Maryland-based fund reported 303,483 shares. Foster And Motley holds 1.74% or 282,792 shares. Knott David M accumulated 14.93% or 978,676 shares. Patten & Patten Tn stated it has 155,865 shares or 0.59% of all its holdings. Beach Inv Counsel Pa has 0.58% invested in Pfizer Inc. (NYSE:PFE). Sumitomo Mitsui Asset Mgmt Company Limited invested in 0.32% or 567,631 shares. Dynamic Advsr Solutions Lc has 26,608 shares for 0.38% of their portfolio. Rmb Capital Mngmt Limited Liability Co owns 0.18% invested in Pfizer Inc. (NYSE:PFE) for 191,571 shares. Patten Grp Inc Incorporated has invested 0.07% in Pfizer Inc. (NYSE:PFE). Tru Department Mb Natl Bank N A has 23,574 shares for 0.09% of their portfolio. Ntv Asset Management Lc has invested 1.05% of its portfolio in Pfizer Inc. (NYSE:PFE).

Since August 4, 2017, it had 0 insider buys, and 10 insider sales for $16.36 million activity. Another trade for 94,409 shares valued at $3.21M was made by DAMELIO FRANK A on Thursday, August 31. SUSMAN SALLY also sold $1.34 million worth of Pfizer Inc. (NYSE:PFE) shares. $263,693 worth of Pfizer Inc. (NYSE:PFE) shares were sold by OLSON LAURIE J. 8,000 shares were sold by JOHNSON RADY A, worth $296,560. READ IAN C had sold 96,950 shares worth $3.30M on Friday, August 4.

Analysts expect Pfizer Inc. (NYSE:PFE) to report $0.56 EPS on January, 30.They anticipate $0.09 EPS change or 19.15 % from last quarter’s $0.47 EPS. PFE’s profit would be $3.34 billion giving it 16.49 P/E if the $0.56 EPS is correct. After having $0.67 EPS previously, Pfizer Inc.’s analysts see -16.42 % EPS growth. The stock decreased 0.14% or $0.05 during the last trading session, reaching $36.94. About 29.54 million shares traded or 85.78% up from the average. Pfizer Inc. (NYSE:PFE) has declined 2.76% since January 21, 2017 and is downtrending. It has underperformed by 19.46% the S&P500.

Pfizer Inc. (NYSE:PFE) Ratings Coverage

Among 21 analysts covering Pfizer (NYSE:PFE), 9 have Buy rating, 1 Sell and 11 Hold. Therefore 43% are positive. Pfizer had 68 analyst reports since July 29, 2015 according to SRatingsIntel. The stock of Pfizer Inc. (NYSE:PFE) has “Hold” rating given on Thursday, July 13 by Jefferies. The rating was maintained by Argus Research with “Buy” on Wednesday, July 29. As per Tuesday, September 5, the company rating was maintained by BMO Capital Markets. On Friday, March 24 the stock rating was maintained by Societe Generale with “Neutral”. BMO Capital Markets maintained the stock with “Hold” rating in Monday, June 12 report. The company was initiated on Friday, December 2 by Guggenheim. The company was maintained on Monday, October 16 by SunTrust. As per Friday, August 28, the company rating was maintained by Piper Jaffray. The rating was upgraded by Barclays Capital on Tuesday, November 29 to “Overweight”. Jefferies maintained the stock with “Buy” rating in Thursday, April 7 report.

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. The company has market cap of $220.19 billion. It operates through two divisions, Pfizer Innovative Health and Pfizer Essential Health (EH). It has a 22.82 P/E ratio. The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

More notable recent Pfizer Inc. (NYSE:PFE) news were published by: Seekingalpha.com which released: “Hold On To Pfizer In 2018” on December 29, 2017, also Seekingalpha.com with their article: “Pfizer: The Best Big Pharma Dividend Stock” published on January 21, 2018, Investorplace.com published: “How Pfizer Inc. Stock Is Positioning for Solid Growth Ahead” on December 28, 2017. More interesting news about Pfizer Inc. (NYSE:PFE) were released by: Reuters.com and their article: “Pfizer ends research for new Alzheimer’s, Parkinson’s drugs” published on January 07, 2018 as well as Prnewswire.com‘s news article titled: “Arvinas Announces Research Collaboration and License Agreement with Pfizer Inc …” with publication date: January 04, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.